Related Experiment Video
Updated: Jul 12, 2025

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
Published on: December 23, 2022
Precise Lipidomics Decipher Circulating Ceramide and Sphingomyelin Cycle Associated with the Progression of
Hemi Luan1, Shuailong Chen2, Longshan Zhao2
1Department of Biomedical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong 510006, China.
Abstract:
Rheumatoid arthritis (RA) is a long-term autoimmune condition that causes joint and surrounding tissue inflammation. Lipid mediators are involved in inflammation and deterioration of the joints. Despite attempts to discover effective drug targets to intervene with lipid metabolism in the disease, progress has been limited. In this study, precise lipidomic technology was employed to quantify a broad range of serum ceramides and sphingomyelin (SM) in a large cohort, revealing an association between the accumulation of circulating ceramides and disturbed ceramide/SM cycles during the progression of RA. In our investigation, we discovered that eight ceramides exhibited a positive correlation with the activity of RA, thereby enhancing the accuracy of RA diagnosis, particularly in patients with serum antibody-negative RA. Furthermore, the enzyme SM phosphodiesterase 3 (SMPD3) was found to disrupt the circulating SM cycle and accelerate the progression of RA. The activity of SMPD3 can be inhibited by methotrexate, resulting in decreased metabolic conversion of SM to ceramide. These findings suggest that targeting the SM cycle may provide a new therapeutic option for RA.
Insights
Researchers found that specific ceramides and sphingomyelin (SM) cycles are linked to rheumatoid arthritis (RA) progression. Targeting these lipid pathways, particularly involving SMPD3, may offer new therapeutic strategies for RA patients.
Area of Science:
- Biochemistry
- Immunology
- Rheumatology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
- Lipid mediators play a role in RA pathogenesis and joint damage.
- Current therapeutic targets for RA related to lipid metabolism have shown limited success.
Purpose of the Study:
- To investigate the role of serum ceramides and sphingomyelin (SM) in rheumatoid arthritis.
- To identify novel diagnostic biomarkers for RA, including antibody-negative RA.
- To explore potential therapeutic targets within the ceramide/SM metabolic cycle.
Main Methods:
- Utilized precise lipidomic technology to quantify serum ceramides and SM in a large patient cohort.
- Analyzed the correlation between specific lipid species and RA activity.
- Investigated the role of sphingomyelin phosphodiesterase 3 (SMPD3) in RA pathogenesis.
Main Results:
- Identified an association between accumulating circulating ceramides and disrupted ceramide/SM cycles in RA progression.
- Found that eight ceramides positively correlate with RA activity, improving diagnostic accuracy, especially in antibody-negative RA.
- Demonstrated that SMPD3 disrupts the SM cycle, accelerating RA, and that methotrexate inhibits SMPD3 activity.
Conclusions:
- Disturbed ceramide/SM cycles are implicated in rheumatoid arthritis.
- Specific ceramides can serve as biomarkers for RA diagnosis and activity.
- Targeting the SM cycle, potentially via SMPD3 inhibition, represents a promising therapeutic avenue for RA.
More Related Videos
11:03A Cryo-pulverization Protocol for Processing Mouse Paws to Evaluate Molecular Pathways of Tissue Inflammation in a Collagen Induced Arthritis Model
Published on: October 30, 2019
09:15Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
Published on: July 18, 2019
Related Concept Videos
Inflammation
Assembly of the Lipid Bilayer in the ER
A large chunk of any biological membrane is composed of phospholipids. These lipids have a heterogeneous distribution across different subcellular organelles and even between...
Asymmetric Lipid Bilayer
The JAK-STAT Signaling Pathway
Lipid Catabolism